A Proposed Brain-, Spine-, and Mental- Health Screening Methodology (NEUROSCREEN) for Healthcare Systems: Position of the Society for Brain Mapping and Therapeutics

Mohammad Nami; Robert Thatcher; Nasser Kashou; Dahabada Lopes; Maria Lobo; Joe F Bolanos; Kevin Morris; Melody Sadri; Teshia Bustos; Gilberto E Sanchez; Alena Mohd-Yusof; John Fiallos; Justin Dye; Xiaofan Guo; Nicholas Peatfield; Milena Asiryan; Alero Mayuku-Dore; Solventa Krakauskaite; Ernesto Palmero Soler; Steven C Cramer; Walter G Besio; Antal Berenyi; Manjari Tripathi; David Hagedorn; Morgan Ingemanson; Marinela Gombosev; Mark Liker; Yousef Salimpour; Martin Mortazavi; Eric Braverman; Leslie S Prichep; Deepak Chopra; Dawn S Eliashiv; Robert Hariri; Ambooj Tiwari; Ken Green; Jason Cormier; Namath Hussain; Nevzat Tarhan; Daniel Sipple; Michael Roy; John S Yu; Aaron Filler; Mike Chen; Chris Wheeler; J Wesson Ashford; Kenneth Blum; Deborah Zelinsky; Vicky Yamamoto; Babak Kateb

doi:10.3233/JAD-215240

A Proposed Brain-, Spine-, and Mental- Health Screening Methodology (NEUROSCREEN) for Healthcare Systems: Position of the Society for Brain Mapping and Therapeutics

J Alzheimers Dis. 2022;86(1):21-42. doi: 10.3233/JAD-215240.

Authors

Mohammad Nami^{1

2

3

4

5}, Robert Thatcher^{1

6}, Nasser Kashou^{1

2}, Dahabada Lopes^{1

2}, Maria Lobo^{1

2}, Joe F Bolanos^{1

2}, Kevin Morris^{1

2}, Melody Sadri^{1

2}, Teshia Bustos^{1

2}, Gilberto E Sanchez^{1

2}, Alena Mohd-Yusof^{1

2}, John Fiallos^{1

2}, Justin Dye⁷, Xiaofan Guo⁸, Nicholas Peatfield⁹, Milena Asiryan^{1

2}, Alero Mayuku-Dore^{1

2}, Solventa Krakauskaite^{1

2}, Ernesto Palmero Soler^{1

2}, Steven C Cramer¹⁰, Walter G Besio¹¹, Antal Berenyi¹², Manjari Tripathi¹³, David Hagedorn¹⁴, Morgan Ingemanson¹⁴, Marinela Gombosev¹⁵, Mark Liker¹⁶, Yousef Salimpour¹⁷, Martin Mortazavi¹⁸, Eric Braverman¹⁹, Leslie S Prichep²⁰, Deepak Chopra²¹, Dawn S Eliashiv^{1

22}, Robert Hariri^{1

2

23

24

25}, Ambooj Tiwari²⁶, Ken Green^{1

2}, Jason Cormier^{1

2

27}, Namath Hussain^{1

28}, Nevzat Tarhan²⁸, Daniel Sipple^{1

2

29}, Michael Roy^{1

2

30}, John S Yu³¹, Aaron Filler^{1

32

31}, Mike Chen^{1

33}, Chris Wheeler^{1

2}, J Wesson Ashford³⁴, Kenneth Blum³⁵, Deborah Zelinsky³⁶, Vicky Yamamoto^{1

2

37

38}, Babak Kateb^{1

2

39

40

25}

Affiliations

¹ Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
² Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
³ Neuroscience Center, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), City of Knowledge, Panama.
⁴ Department of Neuroscience, School of Advanced Medical Sciences and Technologies, and Dana Brain Health Institute, Shiraz University of Medical Sciences, Shiraz, Iran.
⁵ Inclusive Brain Health and BrainLabs International, Swiss Alternative Medicine, Geneva, Switzerland.
⁶ Applied Neuroscience, Inc., St Petersburg, FL, USA.
⁷ Department of Neurosurgery, Loma Linda University, Loma Linda, CA, USA.
⁸ Department of Neurology, Loma Linda University, CA, USA.
⁹ Protome Technologies Inc., Vancouver, Canada.
¹⁰ Department of Neurology, UCLA, and California Rehabilitation Institute, Los Angeles, CA, USA.
¹¹ Electrical Computer and Biomedical Engineering Department and Interdisciplinary Neuroscience Program, University of Rhode Island, RI, USA.
¹² The Neuroscience Institute, New York University, New York, NY, USA.
¹³ Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
¹⁴ Evoke Neuroscience, New York, NY, USA.
¹⁵ SPARK Neuroscience, New York, NY, USA.
¹⁶ Department of Neurosurgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
¹⁷ Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
¹⁸ California Institute of Neuroscience, Thousand Oaks, CA, USA.
¹⁹ PATH Foundation NY, New York, NY, USA.
²⁰ BrainScope Inc., Bethesda, MD, USA.
²¹ The Chopra Foundation, New York, NY, USA.
²² UCLA David Geffen, School of Medicine, Department of Neurology, Los Angeles, CA, USA.
²³ Celularity Corporation, Warren, NJ, USA.
²⁴ Weill Cornell School of Medicine, Department of Neurosurgery, New York, NY, USA.
²⁵ Brain Technology and Innovation Park, Los Angeles, CA, USA.
²⁶ Departments of Neurology, Radiology & Neurosurgery - NYU Grossman School of Medicine, New York, NY, USA.
²⁷ Lafayette Surgical Specialty Hospital, Lafayette, LA, USA.
²⁸ Department of Psychiatry, Faculty of Medicine, Uskudar University, Turkey.
²⁹ Midwest Spine and Brain Institute, Roseville, MN, USA.
³⁰ Uniformed Services University Health Science (USUHS), Baltimore, MD, USA.
³¹ Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
³² Institute for Nerve Medicine, Santa Monica, CA, USA.
³³ Department of Neurosurgery, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
³⁴ Stanford University, Palo Alto, VA, USA.
³⁵ Division of Addiction Research, Center for Psychiatry, Medicine, and Primary Care, Western Health Sciences, Pomona, CA, USA.
³⁶ Mind-Eye Institute, Northbrook, IL, USA.
³⁷ USC Keck School of Medicine, The USC Caruso Department of Otolaryngology-Head and Neck Surgery, Los Angeles, CA, USA.
³⁸ USC-Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
³⁹ Loma Linda University, Department of Neurosurgery, Loma Linda, CA, USA.
⁴⁰ National Center for NanoBioElectronic (NCNBE), Los Angeles, CA, USA.

PMID: 35034899
DOI: 10.3233/JAD-215240

Abstract

The COVID-19 pandemic has accelerated neurological, mental health disorders, and neurocognitive issues. However, there is a lack of inexpensive and efficient brain evaluation and screening systems. As a result, a considerable fraction of patients with neurocognitive or psychobehavioral predicaments either do not get timely diagnosed or fail to receive personalized treatment plans. This is especially true in the elderly populations, wherein only 16% of seniors say they receive regular cognitive evaluations. Therefore, there is a great need for development of an optimized clinical brain screening workflow methodology like what is already in existence for prostate and breast exams. Such a methodology should be designed to facilitate objective early detection and cost-effective treatment of such disorders. In this paper we have reviewed the existing clinical protocols, recent technological advances and suggested reliable clinical workflows for brain screening. Such protocols range from questionnaires and smartphone apps to multi-modality brain mapping and advanced imaging where applicable. To that end, the Society for Brain Mapping and Therapeutics (SBMT) proposes the Brain, Spine and Mental Health Screening (NEUROSCREEN) as a multi-faceted approach. Beside other assessment tools, NEUROSCREEN employs smartphone guided cognitive assessments and quantitative electroencephalography (qEEG) as well as potential genetic testing for cognitive decline risk as inexpensive and effective screening tools to facilitate objective diagnosis, monitor disease progression, and guide personalized treatment interventions. Operationalizing NEUROSCREEN is expected to result in reduced healthcare costs and improving quality of life at national and later, global scales.

Keywords: Brain mapping; brain screening; cMEG; mental health screening; neuro-screening; neurotechnologies; preventive medicine; qEEG.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Aged
Brain / diagnostic imaging
Brain Mapping
COVID-19*
Delivery of Health Care
Humans
Male
Pandemics*
Quality of Life